Abstract
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Cardiac electrophysiology review |
| Vol/bind | 7 |
| Udgave nummer | 3 |
| Sider (fra-til) | 220-4 |
| Antal sider | 4 |
| ISSN | 1385-2264 |
| DOI | |
| Status | Udgivet - 2003 |
Bibliografisk note
Keywords: Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Humans; Multicenter Studies as Topic; Phenethylamines; Randomized Controlled Trials as Topic; Retrospective Studies; Sulfonamides; Ventricular Dysfunction, LeftAdgang til dokumentet
Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
I: Cardiac electrophysiology review, Bind 7, Nr. 3, 2003, s. 220-4.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
}
TY - JOUR
T1 - Does conversion and prevention of atrial fibrillation enhance survival in patients with left ventricular dysfunction? Evidence from the Danish Investigations of Arrhythmia and Mortality ON Dofetilide/(DIAMOND) study
AU - Pedersen, Ole Dyg
AU - Brendorp, Bente
AU - Elming, Hanne
AU - Pehrson, Steen
AU - Køber, Lars
AU - Torp-Pedersen, Christian
N1 - Keywords: Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Humans; Multicenter Studies as Topic; Phenethylamines; Randomized Controlled Trials as Topic; Retrospective Studies; Sulfonamides; Ventricular Dysfunction, Left
PY - 2003
Y1 - 2003
N2 - BACKGROUND: Atrial fibrillation is a common arrhythmia in patients with left ventricular dysfunction associated with increased morbidity and mortality. The present study investigated the potential of dofetilide to restore and maintain sinus rhythm in patients with left ventricular dysfunction, which might reduce mortality and hospitalizations. METHODS AND RESULTS: In the Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) studies, 506 patients were in atrial fibrillation (AF) or atrial flutter (AFl) at baseline. Over the course of study, cardioversion occurred in 148 (59%) dofetilide- and 86 (34%) placebo-treated patients. In these patients, the probability of maintaining sinus rhythm for 1 year was 79% with dofetilide versus 42% with placebo ( P < 0.001). Dofetilide had no effect on all-cause mortality, but restoration and maintenance of sinusrhythm (independent of study treatment) was associated with a significant reduction in mortality (risk ratio [RR], 0.44; 95% CI, 0.30 to 0.64; P < 0.0001). In addition, dofetilide therapy was associated with a significantly lower risk ratio versus placebo for either all-cause (RR, 0.70; 95% CI, 0.56 to 0.89; P < or = 0.005) or congestive heart failure (RR, 0.69; 95% CI, 0.51 to 0.93; P < or = 0.02) rehospitalization. CONCLUSIONS: Dofetilide is safe and increases the probability of obtaining and maintaining sinus rhythm in patients with structural heart disease. The present study suggests that restoration of sinus rhythm--on placebo or dofetilide--is associated with improved survival.
AB - BACKGROUND: Atrial fibrillation is a common arrhythmia in patients with left ventricular dysfunction associated with increased morbidity and mortality. The present study investigated the potential of dofetilide to restore and maintain sinus rhythm in patients with left ventricular dysfunction, which might reduce mortality and hospitalizations. METHODS AND RESULTS: In the Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) studies, 506 patients were in atrial fibrillation (AF) or atrial flutter (AFl) at baseline. Over the course of study, cardioversion occurred in 148 (59%) dofetilide- and 86 (34%) placebo-treated patients. In these patients, the probability of maintaining sinus rhythm for 1 year was 79% with dofetilide versus 42% with placebo ( P < 0.001). Dofetilide had no effect on all-cause mortality, but restoration and maintenance of sinusrhythm (independent of study treatment) was associated with a significant reduction in mortality (risk ratio [RR], 0.44; 95% CI, 0.30 to 0.64; P < 0.0001). In addition, dofetilide therapy was associated with a significantly lower risk ratio versus placebo for either all-cause (RR, 0.70; 95% CI, 0.56 to 0.89; P < or = 0.005) or congestive heart failure (RR, 0.69; 95% CI, 0.51 to 0.93; P < or = 0.02) rehospitalization. CONCLUSIONS: Dofetilide is safe and increases the probability of obtaining and maintaining sinus rhythm in patients with structural heart disease. The present study suggests that restoration of sinus rhythm--on placebo or dofetilide--is associated with improved survival.
U2 - 10.1023/B:CEPR.0000012386.82055.81
DO - 10.1023/B:CEPR.0000012386.82055.81
M3 - Journal article
C2 - 14739717
SN - 1385-2264
VL - 7
SP - 220
EP - 224
JO - Cardiac electrophysiology review
JF - Cardiac electrophysiology review
IS - 3
ER -